High doses of vitamin D cannot improve health outcomes for critically ill patients as such supplements do not decrease mortality or improve other non-fatal outcomes, reveals a new study.

TOP INSIGHT
A deficiency of vitamin D is a common risk factor for worse outcomes in critically ill patients.
"The VIOLET study did not show benefit from vitamin D supplementation in this population of critically ill patients," said Ginde. "However, the study gives us a model to intervene in the earliest stage of critical illness, which will yield improved care and better health for our patients in the future."
In this case, the researchers sought to determine whether vitamin D supplementation could reduce morbidity and mortality in critically ill patients. While vitamin D is most known for strong bone formation, it also helps to fight infections, is a potent anti-inflammatory agent, and is essential for lung development and function.
"We wanted to study whether rapidly correcting vitamin D deficiency could improve outcomes for patients with a critical illness," Talmor said. "Previous studies suggested that this treatment might reduce mortality, so we wanted to definitively show whether high doses of vitamin D could reduce all-cause, all-location 90-day mortality in those critically ill patients."
In this study, the NHLBI PETAL Network conducted a controlled study of patients who needed admission into intensive care units. Among those cases, patients had pneumonia, sepsis, shock, respiratory failure, and other critical conditions.
From April 2017 through July 2018, 2,624 patients at 44 hospitals consented to participate in the study. Of those, 1,360 screened as vitamin D deficient, and ultimately 1,078 were included in the final analysis. About half received vitamin D, and half received a placebo, and the vitamin D group achieved rapid correction of vitamin D deficiency in the blood. Patients were followed for 90 days, and researchers found no difference in mortality rates, hospital length of stay, or time on mechanical ventilation between the two groups.
Source-Eurekalert
MEDINDIA




Email










